The RET (ret proto-oncogene) gene at 10q11 encodes for a transmembrane tyrosine kinase receptor involved in the control of cell differentiation, cell proliferation, and cell survival1.
Rearrangements involving the RET gene are recognised recurrent abnormalities seen in 1-2% patients with lung adenocarcinomas, where it is seen fused with KIF5B2,3, and papillary thyroid carcinoma where it is seen fused to a number of different partner genes including: CCDC6, PRKAR1A and NCOA44,5. The features of the proteins encoded by all types of RET fusion gene are similar to those of ALK: coiled-coil domains in the N-terminal fusion partners cause the RET domains to dimerize, resulting in activation of RET tyrosine kinase in the absence of ligands3.
1. Asai N, et al. Mol Cell Biol. 1995;15(3):1613–9
2. Kohno T et al., Nat Med 2012;18(3):375-7
3. Ju YS et al., Genome Res 2012;22(3):436-45
4. Colato C, et al., Eur J Endocrinol. 2015;172(5):571–82
5. Romei C et al., Front Endocrinol 2012;3:54
- Area of Interest*
- Lung Cancer
This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.